Trial Profile
A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2009
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone disorders; Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Z-NEXT
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 Oct 2009 New trial record